Nagah Elmusharaf

Heath Park, CF14 4XW
Cardiff, WLS, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.

Journal: Blood

Published: September 02, 2025

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine

Published: June 16, 2025

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Journal: The New England journal of medicine

Published: December 11, 2023

Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia.

Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia.

Journal: British journal of haematology

Published: September 11, 2023

Social deprivation independently impacts clinical outcomes in patients with chronic lymphocytic leukemia.

Social deprivation independently impacts clinical outcomes in patients with chronic lymphocytic leukemia.

Journal: Haematologica

Published: May 19, 2023

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: January 16, 2023

Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.

Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.

Journal: British journal of haematology

Published: December 21, 2022

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.

Journal: Therapeutic advances in hematology

Published: October 25, 2022

International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma.

International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma.

Journal: Haematologica

Published: June 28, 2022

Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.

Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.

Journal: British journal of haematology

Published: February 15, 2021

Atypical blood and bone marrow lymphocytes in ALK-positive anaplastic T-cell lymphoma: important lessons.

Atypical blood and bone marrow lymphocytes in ALK-positive anaplastic T-cell lymphoma: important lessons.

Journal: BMJ case reports

Published: September 17, 2013

Showing 1-11 of 11

Last Updated: 09/26/2026